Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/15/22
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 09/01/22
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/15/22
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic OptionsGlobeNewsWire • 08/15/22
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/08/22
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerGlobeNewsWire • 07/19/22
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/17/22
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/17/22
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in MayGlobeNewsWire • 05/03/22
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian CancerGlobeNewsWire • 04/26/22
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian CancerGlobeNewsWire • 03/31/22
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/23/22
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/23/22
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/23/22
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23GlobeNewsWire • 03/14/22